Switching to fingolimod in MS therapy – risk or benefits? Case reports Case report
Main Article Content
Abstract
Approving of disease modifying drugs (DMD) in clinical practice was the breakthrough in the multiple sclerosis therapy. Until now, only interferon beta and glatiramer were used as safe drugs but with limited therapeutic efficacy. Most of validated data suggested that the treatment of multiple sclerosis should be started very early to slow the progression of disease and disability. Approving of new drugs – fingolimod and natalizumab – and the possibility of their reimbursement in Poland are connected with superior benefits in MS therapy. To get the best efficacy and safety of the treatment with new drugs, the inclusion criteria to the therapy and monitoring of adverse events must be performed. Two described cases concern the switching of MS therapy and outcome benefits.
Article Details
Copyright © by Medical Education. All rights reserved.
References
2. Brinkmann V., Billich A., Baumruker T. et al.: Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 2010; 9: 883-897.
3. Chun J., Hartung H.P.: Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin. Neuropharmacol. 2010; 33: 91-101.
4. Kieseier B.C., Wiendl H., Hartung H.P. et al.: The future of multiple sclerosis therapy. Pharmacol. Res 2009; 60: 207-2011.
5. Kappos L., Radue E.W., O’Connor P. et al.; FREEDOMS Study Group: A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 2010; 362: 387-401.
6. Cohen J.A., Barkhof F., Comi G. et al.; TRANSFORMS Study Group: Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 2010; 362: 402-415.
7. Ontaneda D., Hara-Cleaver C., Rudick R.A. et al.: Early tolerability and safety of fingolimod in clinical practice. J. Neurol. Sci. 2012; 323: 167-172.
8. Fazekas F.: Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group. Wien Med. Wochenschr. 2012; 162: 254-366.
9. Kappos L., Cohen J., Collins W. et al.: Fingolimod in relapsing multiple sclerosis: an integrated analysis of safety findings. Mult. Scler. Rel. Dis. 2014; 3: 494-504.